 |
|
|
| Internet Search |
|
Stock Search |
|
|
|
|
|
ABGENIX INC, (ABGX) Stock Rating Learn More
| Our Overall Rating on ABGENIX INC, ABGX is Not Available | | Abgenix, Inc., a biopharmaceutical company, engages in the discovery, development, and manufacture of human therapeutic antibodies for the treatment of various disease conditions, including cancer, inflammation, and metabolic disease. Its antibody therapeutic product candidates, which are in clinical trials, include Panitumumab (ABX-EGF) a human antibody therapeutic product candidate directed against the epidermal growth factor receptor and a candidate for the treatment of various solid tumors; and ABX-PTH, a fully human antibody therapeutic product candidate directed against parathyroid hormone for the treatment of a secondary hyperparathyroidism. Abgenix has collaboration agreement with AstraZeneca UK Limited for the development of antibody therapeutics; and has co-development agreements with various companies, including U3 Pharma AG, Microscience Limited, Dendreon Corporation, Chugai Pharmaceuticals Co., Ltd., and Sosei Co., Ltd. for the joint development of antibody product candidates. The company is headquartered in Fremont, California. | | Our Not Available Rating on ABGX was issued on 11/19/2008 |
ABGENIX INC Technical Rating
|
|
|
|
